CMPX
Income statement / Annual
Last year (2025), Compass Therapeutics Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Compass Therapeutics Inc's net income was -$66.49 M.
See Compass Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
03/31/2020 |
03/31/2019 |
| Operating Revenue |
$0.00 |
$850.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.47 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.92 M
|
| Gross Profit |
-$1.47 M
|
$850.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.92 M
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$55.97 M
|
$42.34 M
|
$38.12 M
|
$30.00 M
|
$20.34 M
|
$14.90 M
|
$22.45 M
|
$27.10 M
|
| General & Administrative Expenses |
$16.87 M
|
$15.13 M
|
$12.24 M
|
$11.66 M
|
$10.93 M
|
$12.91 M
|
$11.60 M
|
$11.22 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.87 M
|
$15.13 M
|
$12.24 M
|
$11.66 M
|
$10.93 M
|
$12.91 M
|
$11.60 M
|
$11.22 M
|
| Other Expenses |
-$1.47 M
|
$0.00
|
$0.00
|
$0.00
|
$50.62 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$71.37 M
|
$57.48 M
|
$50.36 M
|
$41.66 M
|
$81.88 M
|
$27.81 M
|
$34.05 M
|
$38.31 M
|
| Cost And Expenses |
$72.84 M
|
$57.48 M
|
$50.36 M
|
$41.66 M
|
$81.88 M
|
$27.81 M
|
$34.05 M
|
$38.31 M
|
| Interest Income |
$6.35 M
|
$7.30 M
|
$0.00
|
$2.36 M
|
$29.00 K
|
$88.00 K
|
$743.00 K
|
$663.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$2.36 M
|
$370.00 K
|
$908.00 K
|
$1.23 M
|
$767.00 K
|
| Depreciation & Amortization |
$1.47 M
|
$1.75 M
|
$1.89 M
|
$1.90 M
|
$1.62 M
|
$2.40 M
|
$2.12 M
|
$1.92 M
|
| EBITDA |
-$71.37 M |
-$54.87 M |
-$48.47 M |
-$39.75 M |
-$80.19 M |
-$25.41 M |
-$31.93 M |
-$35.73 M |
| EBITDA Ratio |
0
|
-64.56
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-66.62
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.35 M
|
$7.25 M
|
$7.87 M
|
$2.43 M
|
-$299.00 K
|
-$1.66 M
|
-$601.00 K
|
$233.00 K
|
| Income Before Tax |
-$66.49 M
|
-$49.38 M
|
-$42.49 M
|
-$39.23 M
|
-$82.18 M
|
-$29.47 M
|
-$34.65 M
|
-$38.18 M
|
| Income Before Tax Ratio |
0
|
-58.09
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$32.00 K
|
$91.00 K
|
$103.00 K
|
| Net Income |
-$66.49 M
|
-$49.38 M
|
-$42.49 M
|
-$39.23 M
|
-$82.18 M
|
-$29.50 M
|
-$34.74 M
|
-$38.29 M
|
| Net Income Ratio |
0
|
-58.09
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.42 |
-0.36 |
-0.33 |
-0.35 |
-1.31 |
-0.52 |
-0.67 |
-7.66 |
| EPS Diluted |
-0.42 |
-0.36 |
-0.33 |
-0.35 |
-1.31 |
-0.52 |
-0.67 |
-7.66 |
| Weighted Average Shares Out |
$157.70 M
|
$137.11 M
|
$127.03 M
|
$105.19 M
|
$62.87 M
|
$56.22 M
|
$52.11 M
|
$5.00 M
|
| Weighted Average Shares Out Diluted |
$157.70 M
|
$137.11 M
|
$127.03 M
|
$105.19 M
|
$62.87 M
|
$56.22 M
|
$52.11 M
|
$5.00 M
|
| Link |
|
|
|
|
|
|
|
|
